JP2020506690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506690A5 JP2020506690A5 JP2019539937A JP2019539937A JP2020506690A5 JP 2020506690 A5 JP2020506690 A5 JP 2020506690A5 JP 2019539937 A JP2019539937 A JP 2019539937A JP 2019539937 A JP2019539937 A JP 2019539937A JP 2020506690 A5 JP2020506690 A5 JP 2020506690A5
- Authority
- JP
- Japan
- Prior art keywords
- moshiku
- peptide
- pharmaceutically acceptable
- acceptable salt
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 16
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023135232A JP2023179415A (ja) | 2017-01-27 | 2023-08-23 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451255P | 2017-01-27 | 2017-01-27 | |
| DE102017101671.6 | 2017-01-27 | ||
| DE102017101671 | 2017-01-27 | ||
| US62/451,255 | 2017-01-27 | ||
| PCT/EP2018/051952 WO2018138257A1 (en) | 2017-01-27 | 2018-01-26 | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135232A Division JP2023179415A (ja) | 2017-01-27 | 2023-08-23 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506690A JP2020506690A (ja) | 2020-03-05 |
| JP2020506690A5 true JP2020506690A5 (OSRAM) | 2021-03-04 |
| JP7337695B2 JP7337695B2 (ja) | 2023-09-04 |
Family
ID=61148200
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539937A Active JP7337695B2 (ja) | 2017-01-27 | 2018-01-26 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ |
| JP2023135232A Pending JP2023179415A (ja) | 2017-01-27 | 2023-08-23 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135232A Pending JP2023179415A (ja) | 2017-01-27 | 2023-08-23 | 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチド組み合わせ |
Country Status (23)
| Country | Link |
|---|---|
| US (10) | US11248035B1 (OSRAM) |
| EP (2) | EP4035675A3 (OSRAM) |
| JP (2) | JP7337695B2 (OSRAM) |
| KR (2) | KR102699622B1 (OSRAM) |
| CN (1) | CN110198734A (OSRAM) |
| AU (6) | AU2018212584B2 (OSRAM) |
| BR (1) | BR112019015237A2 (OSRAM) |
| CA (1) | CA3048108A1 (OSRAM) |
| CL (8) | CL2019002093A1 (OSRAM) |
| CO (1) | CO2019008008A2 (OSRAM) |
| CR (4) | CR20210128A (OSRAM) |
| ES (1) | ES2946584T3 (OSRAM) |
| HR (1) | HRP20230512T8 (OSRAM) |
| IL (2) | IL299051A (OSRAM) |
| LT (1) | LT3573647T (OSRAM) |
| MX (1) | MX2019008843A (OSRAM) |
| NZ (1) | NZ754139A (OSRAM) |
| PE (1) | PE20191248A1 (OSRAM) |
| PH (1) | PH12019501377A1 (OSRAM) |
| RS (1) | RS64217B1 (OSRAM) |
| SG (2) | SG10202108122YA (OSRAM) |
| SI (1) | SI3573647T1 (OSRAM) |
| TW (1) | TW202325724A (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| CR20210128A (es) | 2017-01-27 | 2021-04-26 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388) |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| DE202020005554U1 (de) | 2019-08-28 | 2022-02-03 | Dairycs Automatic Milking Ltd. | Ein Milchviehbetrieb mit mindestens einer vorderen Hochbahn |
| AU2020384953A1 (en) * | 2019-11-11 | 2022-06-23 | Ibi-Ag Innovative Bio Insecticides Ltd. | Insect control nanobodies and uses thereof |
| CN110838372B (zh) * | 2019-11-18 | 2022-07-12 | 武汉大学 | 一种个性化癌症用药数据库系统及建立方法 |
| CN111363744B (zh) * | 2020-02-26 | 2021-08-24 | 暨南大学 | 小檗碱介导的uhrf1基因抑制及其在制备治疗多发性骨髓瘤药物中的用途 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN114107502A (zh) * | 2021-11-29 | 2022-03-01 | 四川大学华西医院 | 一种上尿路上皮癌诊断标志物及其应用 |
| CN115948557B (zh) * | 2023-01-04 | 2025-09-02 | 陕西师范大学 | 一种nlrp2作为靶点在卵巢癌疾病诊断和/或治疗中的应用 |
| CN116350787B (zh) * | 2023-03-15 | 2025-04-01 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Rbm15的抑制剂在卵巢癌紫杉醇化疗耐药中的应用 |
| CN117210561A (zh) * | 2023-05-09 | 2023-12-12 | 山东第一医科大学第一附属医院(山东省千佛山医院) | Rnf106在食管鳞癌检测、治疗和预后靶点及应用 |
| CN116590263A (zh) * | 2023-07-02 | 2023-08-15 | 广州庆毅生物医药科技有限公司 | 一种重组蛋白、单克隆抗体及其检测试剂盒和应用 |
| CN117233393B (zh) * | 2023-11-15 | 2024-02-09 | 四川大学华西医院 | 双重免疫组化染色试剂盒及其在鉴别良恶性胆管上皮肿瘤中的应用 |
| CN118166098B (zh) * | 2024-02-05 | 2024-09-10 | 北京大学深圳医院 | 检测magea4-as1的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4410397A (en) * | 1996-09-06 | 1998-03-26 | Brigham And Women's Hospital | Inhibition of mast cell activation by gp49-based mechanisms and reagents |
| US6514935B1 (en) * | 1997-03-14 | 2003-02-04 | President And Fellows Of Harvard | Methods of treating hypertension |
| GB0017512D0 (en) * | 2000-07-17 | 2000-08-30 | Smithkline Beecham Biolog | Novel compounds |
| US7285631B2 (en) * | 2001-08-10 | 2007-10-23 | Serono Genetics Institute S.A. | Human cDNAs and proteins and uses thereof |
| WO2003016475A2 (en) * | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US6906036B2 (en) * | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CN1691964A (zh) * | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
| WO2005017102A2 (en) * | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| KR101216655B1 (ko) * | 2003-11-19 | 2013-01-02 | 수르벡 에이피에스 | Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도 |
| EP1859266A4 (en) * | 2005-02-24 | 2010-07-28 | Cemines Inc | COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES |
| ES2341802T3 (es) | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| EP2125005B1 (en) * | 2007-03-26 | 2015-04-08 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Prame derived peptides and immunogenic compositions comprising these |
| PL2562184T3 (pl) | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| SI2280721T1 (en) * | 2008-04-17 | 2018-02-28 | Io Biotech Aps C/O Cobis | Indoleamine 2, 3-dioxygenase based immunotherapy |
| EP2113253B1 (en) * | 2008-04-30 | 2010-03-31 | Immatics Biotechnologies GmbH | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
| NO2119726T3 (OSRAM) | 2008-05-14 | 2015-05-23 | ||
| WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US8710014B2 (en) | 2010-10-08 | 2014-04-29 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of MMP13:MMP-substrate interactions |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| CR20210128A (es) | 2017-01-27 | 2021-04-26 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388) |
| US10738100B2 (en) * | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| TW202028224A (zh) | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
-
2018
- 2018-01-26 CR CR20210128A patent/CR20210128A/es unknown
- 2018-01-26 SG SG10202108122YA patent/SG10202108122YA/en unknown
- 2018-01-26 ES ES18702642T patent/ES2946584T3/es active Active
- 2018-01-26 PE PE2019001476A patent/PE20191248A1/es unknown
- 2018-01-26 JP JP2019539937A patent/JP7337695B2/ja active Active
- 2018-01-26 CR CR20190388A patent/CR20190388A/es unknown
- 2018-01-26 AU AU2018212584A patent/AU2018212584B2/en not_active Ceased
- 2018-01-26 EP EP22151693.3A patent/EP4035675A3/en active Pending
- 2018-01-26 SG SG11201906198PA patent/SG11201906198PA/en unknown
- 2018-01-26 NZ NZ754139A patent/NZ754139A/en not_active IP Right Cessation
- 2018-01-26 TW TW112105929A patent/TW202325724A/zh unknown
- 2018-01-26 KR KR1020197022277A patent/KR102699622B1/ko active Active
- 2018-01-26 CR CR20210129A patent/CR20210129A/es unknown
- 2018-01-26 RS RS20230396A patent/RS64217B1/sr unknown
- 2018-01-26 CA CA3048108A patent/CA3048108A1/en active Pending
- 2018-01-26 IL IL299051A patent/IL299051A/en unknown
- 2018-01-26 LT LTEPPCT/EP2018/051952T patent/LT3573647T/lt unknown
- 2018-01-26 KR KR1020247028280A patent/KR20240134224A/ko active Pending
- 2018-01-26 SI SI201830920T patent/SI3573647T1/sl unknown
- 2018-01-26 BR BR112019015237A patent/BR112019015237A2/pt not_active Application Discontinuation
- 2018-01-26 MX MX2019008843A patent/MX2019008843A/es unknown
- 2018-01-26 EP EP18702642.2A patent/EP3573647B1/en active Active
- 2018-01-26 HR HRP20230512TT patent/HRP20230512T8/hr unknown
- 2018-01-26 CN CN201880008006.XA patent/CN110198734A/zh active Pending
- 2018-01-26 CR CR20210130A patent/CR20210130A/es unknown
-
2019
- 2019-06-17 PH PH12019501377A patent/PH12019501377A1/en unknown
- 2019-07-25 CO CONC2019/0008008A patent/CO2019008008A2/es unknown
- 2019-07-25 IL IL268278A patent/IL268278B2/en unknown
- 2019-07-26 CL CL2019002093A patent/CL2019002093A1/es unknown
-
2020
- 2020-03-30 CL CL2020000817A patent/CL2020000817A1/es unknown
-
2021
- 2021-03-02 AU AU2021201347A patent/AU2021201347A1/en not_active Abandoned
- 2021-03-02 AU AU2021201349A patent/AU2021201349A1/en not_active Abandoned
- 2021-03-02 AU AU2021201348A patent/AU2021201348A1/en not_active Abandoned
- 2021-03-02 AU AU2021201350A patent/AU2021201350B9/en not_active Ceased
- 2021-03-02 AU AU2021201346A patent/AU2021201346A1/en not_active Abandoned
- 2021-06-11 US US17/345,211 patent/US11248035B1/en active Active
- 2021-06-17 US US17/350,879 patent/US11858978B2/en active Active
- 2021-06-17 US US17/350,964 patent/US11214608B2/en active Active
- 2021-09-02 US US17/465,381 patent/US11919940B2/en active Active
- 2021-09-02 US US17/465,426 patent/US12065477B2/en active Active
- 2021-09-02 US US17/465,460 patent/US11345737B1/en active Active
- 2021-09-22 CL CL2021002460A patent/CL2021002460A1/es unknown
- 2021-09-22 CL CL2021002459A patent/CL2021002459A1/es unknown
- 2021-09-22 CL CL2021002461A patent/CL2021002461A1/es unknown
-
2022
- 2022-10-21 CL CL2022002923A patent/CL2022002923A1/es unknown
- 2022-12-01 CL CL2022003407A patent/CL2022003407A1/es unknown
- 2022-12-01 CL CL2022003406A patent/CL2022003406A1/es unknown
-
2023
- 2023-03-30 US US18/192,752 patent/US20240076349A1/en active Pending
- 2023-03-30 US US18/192,743 patent/US20240034769A1/en active Pending
- 2023-04-07 US US18/297,064 patent/US20230365651A1/en active Pending
- 2023-04-07 US US18/297,069 patent/US20230312680A1/en active Pending
- 2023-08-23 JP JP2023135232A patent/JP2023179415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506690A5 (OSRAM) | ||
| JP2021101700A5 (OSRAM) | ||
| JP2019513005A5 (OSRAM) | ||
| JP2020198875A5 (OSRAM) | ||
| JP2020182458A5 (OSRAM) | ||
| JP2020191862A5 (OSRAM) | ||
| JP2019536426A5 (OSRAM) | ||
| JP2019516663A5 (OSRAM) | ||
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| JP2020516681A5 (OSRAM) | ||
| JP2019515653A5 (OSRAM) | ||
| JP2022101576A (ja) | スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） | |
| EP2590679B1 (en) | Immunomodulatory protein constructs with a helical polymeric backbone | |
| JP6566938B2 (ja) | 免疫療法のための組成物及び方法 | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2011520436A5 (OSRAM) | ||
| JP2019520038A5 (OSRAM) | ||
| JP2022125216A (ja) | 糖尿病の治療のためのペプチド及び方法 | |
| CN106008716A (zh) | 呼吸道合胞病毒抗原组合物和方法 | |
| WO2021216738A2 (en) | Compositions and methods of generating an immune response | |
| CN107488235B (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| FI3273986T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan | |
| Zhang et al. | Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model | |
| CN106110320A (zh) | 抗原性组合物和方法 | |
| CN109641936A (zh) | 用于癌症疫苗中的pdl1肽 |